Get caught up with Contemporary OB/GYN's latest coverage from The Menopause Society Annual Meeting in San Diego, California.
|Articles|September 21, 2006
Roberta Speyer Introduces OBGYN.net to China-OBGYN.net Video
Author(s)Roberta Speyer
OBGYN.net Conference CoverageOBGYN.net visits China-OBGYN.net in a meeting underwritten by InSightecMarch 2006
Advertisement
The file you requested will begin playing automatically. If it does not, press the 'play' button. If you experience playback problems, make certain you have the latest version of Windows Media Player, available
Advertisement
Related to this article
Misread Women’s Health Initiative data sidelined hormone therapy and menopause education, according to Mary Jane Minkin, MD, FACOG.
Susan Reed, MD, on the MsFLASH network's pooled findings, including nonhormonal therapies comparable to low-dose estradiol and CBT for sleep.
Late recurrence, high-risk features, and treatment failure can signal midlife night sweats aren’t menopause, according to Cheryl Cox Kinney, MD.
Hormone therapy was associated with more frequent, longer migraines in postmenopausal women, but not with greater severity or analgesic use.
JoAnn V. Pinkerton, MD, offers primary care counseling on elinzanetant's side effects and the early onset and continued relief of hot flashes.
Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
TMS 2026: HSDD biopsychosocial approach, night sweats red flags, misread WHI data
2
Neurokinin receptor antagonists improve menopausal sleep disturbance
3
How misread WHI data reshaped menopause care and training
4
Red flags that point beyond menopause in patients with night sweats
5